Several brokerages have updated their recommendations and price targets on shares of ARMO Biosciences (NASDAQ: ARMO) in the last few weeks:
Shares of ARMO Biosciences Inc (ARMO) opened at $50.53 on Wednesday. ARMO Biosciences Inc has a 12 month low of $27.00 and a 12 month high of $57.19.
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.